Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Adv Ther (Weinh). 2021 Jan 20;4(4):2000244. doi: 10.1002/adtp.202000244

Figure 1. dg-Bcan is expressed in primary and recurrent glioma tissues and cells.

Figure 1.

a) Immunofluorescence images of frozen GBM specimens (using BG1 antibody) showing dg-Bcan (red) and nuclei (blue). Scale bar: 500 μm. b) Western blot of high-grade glioma tissues (grade III or GBM) and control samples (using pan-brevican antibody) with corresponding clinical information (tables). PMI: Post-mortem interval for samples that were recovered after autopsy. c) Immunofluorescence images of patient-derived glioma cells (PDGCs) (using BG1 antibody) showing dg-Bcan (red) and nuclei (blue). (20x scale bar 100μm, 40x scale bar 50μm) d) Brevican RNA level in PDGCs analyzed by qRT-PCR (n = 3).